Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rei Umezawa

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
Journal of Radiation Research|September 1, 2021
Clinical predictors of severe late urinary toxicity after curative intensity-modulated radiation therapy for localized prostate cancerKen Takeda, Rei Umezawa, Yojiro Ishikawa, et al.
Advances in Radiation Oncology|December 11, 2020
Dose-Dependent Radiation-Induced Myocardial Damage in Esophageal Cancer Treated With Chemoradiotherapy: A Prospective Cardiac Magnetic Resonance Imaging StudyRei Umezawa, Noriyuki Kadoya, Hideki Ota, et al.
Radiation Oncology (London, England)|May 28, 2016
Renal atrophy after stereotactic body radiotherapy for renal cell carcinomaTakaya Yamamoto, Noriyuki Kadoya, Ken Takeda, et al.
The Tohoku Journal of Experimental Medicine|November 13, 2015
Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular CarcinomaYasuteru Kondo, Osamu Kimura, Takayuki Kogure, et al.
Journal of Radiation Research|July 17, 2016
Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical studyNoriyoshi Takahashi, Takaya Yamamoto, Haruo Matsushita, et al.
Radiation Oncology (London, England)|November 8, 2011
Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/mlRei Umezawa, Hisanori Ariga, Yoshihiro Ogawa, et al.
Plos One|December 2, 2022
Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancerTakaya Yamamoto, Yoshiyuki Katsuta, Kiyokazu Sato, et al.
Journal of Radiation Research|May 9, 2026
Feasibility of retrieval-augmented generation for large language models with Japanese input in radiotherapyYoshiyuki Takahashi, Noriyuki Kadoya, Kazuhiro Arai, et al.
Asian Journal of Urology|May 8, 2019
Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factorRei Umezawa, Koji Inaba, Satoshi Nakamura, et al.
BMC Cancer|October 29, 2015
Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocolsRei Umezawa, Keiichi Jingu, Haruo Matsushita, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Journal of Radiation Research|September 1, 2021
Clinical predictors of severe late urinary toxicity after curative intensity-modulated radiation therapy for localized prostate cancerKen Takeda, Rei Umezawa, Yojiro Ishikawa, et al.
Advances in Radiation Oncology|December 11, 2020
Dose-Dependent Radiation-Induced Myocardial Damage in Esophageal Cancer Treated With Chemoradiotherapy: A Prospective Cardiac Magnetic Resonance Imaging StudyRei Umezawa, Noriyuki Kadoya, Hideki Ota, et al.
Radiation Oncology (London, England)|May 28, 2016
Renal atrophy after stereotactic body radiotherapy for renal cell carcinomaTakaya Yamamoto, Noriyuki Kadoya, Ken Takeda, et al.
The Tohoku Journal of Experimental Medicine|November 13, 2015
Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular CarcinomaYasuteru Kondo, Osamu Kimura, Takayuki Kogure, et al.
Journal of Radiation Research|July 17, 2016
Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical studyNoriyoshi Takahashi, Takaya Yamamoto, Haruo Matsushita, et al.
Radiation Oncology (London, England)|November 8, 2011
Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/mlRei Umezawa, Hisanori Ariga, Yoshihiro Ogawa, et al.
Plos One|December 2, 2022
Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancerTakaya Yamamoto, Yoshiyuki Katsuta, Kiyokazu Sato, et al.
Journal of Radiation Research|May 9, 2026
Feasibility of retrieval-augmented generation for large language models with Japanese input in radiotherapyYoshiyuki Takahashi, Noriyuki Kadoya, Kazuhiro Arai, et al.
Asian Journal of Urology|May 8, 2019
Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factorRei Umezawa, Koji Inaba, Satoshi Nakamura, et al.
BMC Cancer|October 29, 2015
Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocolsRei Umezawa, Keiichi Jingu, Haruo Matsushita, et al.
Pageof 14